Management of Atopic Dermatitis: The Role of Tacrolimus.
| Autor: | Umar BU; Medical Education, Oxford College of Arts, Business and Technology, Toronto, CAN., Rahman S; School of Medicine, American University of Integrative Sciences, Bridgetown, BRB., Dutta S; Pharmacology, All India Institute of Medical Sciences, Rajkot, Rajkot, IND., Islam T; Community Medicine, Gonoshasthaya Samaj Vittik Medical College, Dhaka, BGD., Nusrat N; Pediatrics, Delta Medical College & Hospital, Dhaka, BGD., Chowdhury K; Pediatrics, Gonoshasthaya Samaj Vittik Medical College, Dhaka, BGD., Binti Wan Ahmad Fakuradzi WFS; Community Medicine, Faculty of Medicine and Defence Health, Universiti Pertahanan Nasional Malaysia (National Defence University of Malaysia), Kuala Lumpur, MYS., Haque M; Pharmacology and Therapeutics, National Defence University of Malaysia, Kuala Lumpur, MYS. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2022 Aug 18; Vol. 14 (8), pp. e28130. Date of Electronic Publication: 2022 Aug 18 (Print Publication: 2022). |
| DOI: | 10.7759/cureus.28130 |
| Abstrakt: | Atopic dermatitis (AD) is a long-lasting inflammatory dermatological condition characterized by itchy, eczematous, sparsely tiny blisters that hold a clear watery substance. Additionally, the diseased skin can suppurate, occasionally with weeping with thickening of the affected skin. This is considered one of the top skin disorders involving both children and adult populations globally. The principal therapeutic intervention for AD is long-standing topical glucocorticoids, which have been used for several decades. Corticosteroid therapy brings several adverse drug effects (ADRs), including irreversible skin atrophy. Tacrolimus belongs to the class of calcineurin inhibitors, which is a type of immunomodulator possessing promising efficacy in treating AD. Topical tacrolimus is an effective and safe non-corticosteroid substitute treatment for AD. We reviewed the available literature to compare and institute the safety, efficacy, and effectiveness of tacrolimus when equated to corticosteroid therapy in managing AD. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2022, Umar et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|